Muhammad Naseem Khan

Muhammad Naseem Khan

Auto-generated profile, based on publicly available information

Muhammad Naseem Khan

Department of Chemistry, COMSATS Institute of Information Technology, University Road, Abbottabad 22060, KPK, Pakistan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Bioorganic Chemistry
Verified
Journal Article
Closed access
DRDr. Fazal Rahim
Dr. Fazal Rahim
HUHayat Ullah
Hayat Ullah
MJMuhammad Tariq Javid
Muhammad Tariq Javid
AWAbdul Wadood
Abdul Wadood
MTMuhammad Taha
Muhammad Taha
KKKhalid Mohammed Khan
Khalid Mohammed Khan

1 October 2016 in Bioorganic Chemistry
Verified
Journal Article
Closed access
DRDr. Fazal Rahim
Dr. Fazal Rahim
HUHayat Ullah
Hayat Ullah
MTMuhammad Taha
Muhammad Taha
AWAbdul Wadood
Abdul Wadood
MJMuhammad Tariq Javed
Muhammad Tariq Javed
KKKhalid Mohammed Khan
Khalid Mohammed Khan

1 January 2018 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MTMuhammad Taha
Muhammad Taha
HUHayat Ullah
Hayat Ullah
LMLaode Muhammad Ramadhan Al Muqarrabun
Laode Muhammad Ramadhan Al Muqarrabun
MKMuhammad Naseem Khan
Muhammad Naseem Khan
FRFazal Rahim
Fazal Rahim
KKKhalid Mohammed Khan
Khalid Mohammed Khan

1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MTMuhammad Taha
Muhammad Taha
HUHayat Ullah
Hayat Ullah
LMLaode Muhammad Ramadhan Al Muqarrabun
Laode Muhammad Ramadhan Al Muqarrabun
MKMuhammad Naseem Khan
Muhammad Naseem Khan
FRFazal Rahim
Fazal Rahim
SPShahnaz Perveen
Shahnaz Perveen

1 October 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MTMuhammad Taha
Muhammad Taha
MBMohd Syukri Baharudin
Mohd Syukri Baharudin
NINor Hadiani Ismail
Nor Hadiani Ismail
SISyahrul Imran
Syahrul Imran
MKMuhammad Naseem Khan
Muhammad Naseem Khan
SVShantini Vijayabalan
Shantini Vijayabalan

9 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMuhammad Naseem Khan
Muhammad Naseem Khan
UFUmar Farooq
Umar Farooq
AKAneela Khushal
Aneela Khushal
TWTanveer A. Wani
Tanveer A. Wani
SZSeema Zargar
Seema Zargar
SKSara Khan
Sara Khan
EGFR is critical for tumor angiogenesis and cancer progression, but existing treatments like erlotinib face limitations such as acquired resistance and side effects. To address these issues, this study employs structure-based drug design techniques including virtual screening, molecular docking, and molecular dynamics simulations to identify new small molecule inhibitors targeting the EGFR kinase domain. From an initial selection of 633,000 compounds from diverse databases, top candidates were identified based on their binding affinity and stability. The virtual screening and docking analyses revealed compounds with higher binding scores than erlotinib. Molecular dynamics simulations and Anisotropic Network Model (ANM) analysis uniquely report that EGFR undergoes significant conformational shifts: inward flap movements in the bound state stabilize a closed conformation, while outward movements in the free state result in a more open conformation. Among the identified inhibitors, compounds such as JFD00243, NPA015124, and others exhibited strong binding affinities and stable interactions with both active and inactive forms of EGFR. Notably, JFD00243 was effective in targeting EGFR in both active and inactive conformations. These findings suggest that the identified inhibitors could potentially overcome current treatment limitations and improve targeted cancer therapies by effectively inhibiting EGFR-mediated tumor angiogenesis.